Commonwealth Equity Services LLC Boosts Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Commonwealth Equity Services LLC raised its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 34.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,382 shares of the biopharmaceutical company’s stock after buying an additional 5,210 shares during the period. Commonwealth Equity Services LLC’s holdings in Halozyme Therapeutics were worth $1,067,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in Halozyme Therapeutics by 96.6% during the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 254 shares during the period. Fifth Third Bancorp increased its holdings in Halozyme Therapeutics by 2.4% during the second quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 261 shares during the last quarter. FCF Advisors LLC raised its position in Halozyme Therapeutics by 1.9% in the first quarter. FCF Advisors LLC now owns 21,164 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 391 shares during the period. New York State Teachers Retirement System raised its position in Halozyme Therapeutics by 0.4% in the first quarter. New York State Teachers Retirement System now owns 113,820 shares of the biopharmaceutical company’s stock worth $4,630,000 after acquiring an additional 400 shares during the period. Finally, Retirement Systems of Alabama boosted its stake in Halozyme Therapeutics by 0.3% in the first quarter. Retirement Systems of Alabama now owns 165,881 shares of the biopharmaceutical company’s stock valued at $6,748,000 after acquiring an additional 436 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, CEO Helen Torley sold 10,000 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the transaction, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $40,063,244.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total transaction of $269,650.00. Following the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at $834,836.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 74,881 shares of company stock valued at $4,267,884. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Up 1.0 %

HALO stock opened at $62.91 on Tuesday. The stock has a 50-day simple moving average of $57.77 and a two-hundred day simple moving average of $48.71. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $65.53. The firm has a market capitalization of $8.01 billion, a PE ratio of 26.00, a PEG ratio of 0.57 and a beta of 1.28. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The company had revenue of $231.40 million during the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. Halozyme Therapeutics’s revenue was up 4.7% compared to the same quarter last year. During the same period last year, the business earned $0.68 earnings per share. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on HALO shares. Benchmark restated a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the stock from $48.00 to $51.00 in a research report on Friday, June 7th. Wells Fargo & Company upped their price target on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Morgan Stanley lifted their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group boosted their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $59.44.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.